JPRN-jRCTs031180408招募中3 期
Prospective Comparison of SGLT-2 inhibitor, Luseogliflozin,versus GLP-1 Receptor Agonist,Dulaglutide, on Regression of Coronary Atherosclerosis with Type 2 Diabetes Mellitus who have Undergone Percutaneous Coronary Intervention: Open-label Randomized Parallel-group Trial - STILL-GLORY trial
Aso Yoshimasa0 个研究点目标入组 200 人开始时间: 2019年3月22日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Provision of informed consent before any study specific procedures
- •1 Age from 20 to 80 years old
- •2 Gender free , Both
- •3 history of cardiovascular complications and post angioplasty
- •4 Type 2 diabetes who have inadequate glycemic control . less than 6.0%(HbA1c)
- •excluded to administration of SGLT2 inhibitor, GLP-1 receptor agonist
排除标准
- •1; Type I diabetes, Diabetes related from pancreas dysfunction
- •2; Diabetic ketoacidosis, Diabetic coma, and sever infection
- •3; contraindication to SGLT-2 inhibitor and GLP-1 receptor agonist on Attachments
- •4; Heart disease, Liver disease (hepatic enzymes more than three times the upper limit of normal ranges) or Impaired kidney function
- •5; acute heart failure (NYHA IV)
- •6; familial hypercholesterolemia (Homozygous)
- •7; Pregnancy or suspicion of pregnancy
- •8; Administration of SGLT2 inhibitor,GLP-1 receptor agonist before starting trial.
- •9; User of PCSK9 inhibitor
- •10; Patients judged as nonconforming in this study
研究者
相似试验
招募中
不适用
Prospective Comparison of SGLT-2 inhibitor, Luseogliflozin,versus GLP-1 Receptor Agonist,Dulaglutide, on Regression of Coronary Atherosclerosis with Type 2 Diabetes Mellitus who have Undergone Percutaneous Coronary Intervention: Open-label Randomized Parallel-group TrialType 2 diabetes who have undergone percutaneous coronary interventionJPRN-UMIN000026630Dokkyo medical university hospital200
招募中
4 期
Efficacy of SGLT2 inhibitor for Non-Alcoholic Fatty Liver Diseaseon Alcoholic Fatty Liver DiseaseC06.552.241.519C18.452.394.750.149ObesityType 2 Diabetes MellitusRBR-48rxwbCentro Educacional Hyarte
已完成
不适用
Comparative trial of SGLT2-inhibitor (Canagliflozin) and sulfonylurea (Glimepiride) for patients with DMDiabetes mellitus type 2JPRN-UMIN000024922Sekino Hospital30
已完成
Unknown
Prospective observational study of tofogliflozin in patients with type 2 diabetesType 2 DiabetesJPRN-jRCT1090220212agoya Medical Association600
已完成
不适用
The efficacy and safety of SGLT2 inhibitor for non alcholic fatty liver disease in Japanese patients with type 2 diabetesJPRN-UMIN000016306Tokyo Medical and Dental University50